Effectiveness of vaccination against COVID-19 in reducing lethality in infected patients
The objective of this study was to estimate vaccine effectiveness against SARS-CoV-2 in reducing mortality from COVID-19 among adults with partial, complete, and booster immunization compared to unvaccinated individuals. A retrospective cohort study was conducted, including adults treated within the...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | Perú |
| Institución: | Colegio Médico del Perú |
| Repositorio: | Acta Médica Peruana |
| Idioma: | español |
| OAI Identifier: | oai:amp.cmp.org.pe:article/3631 |
| Acceso en línea: | https://amp.cmp.org.pe/index.php/AMP/article/view/3631 |
| Access Level: | acceso abierto |
| Palabra clave: | Efectividad de la Vacuna Vacunas Contra la COVID-19 Letalidad COVID-19 Vaccine Efficacy COVID-19 Vaccines Lethality |
| Sumario: | The objective of this study was to estimate vaccine effectiveness against SARS-CoV-2 in reducing mortality from COVID-19 among adults with partial, complete, and booster immunization compared to unvaccinated individuals. A retrospective cohort study was conducted, including adults treated within the Ancash – EsSalud healthcare network (Peru) between January and March 2022, with infection confirmed by RT-PCR and/or antigen tests. Data from NOTICOVID and SINADEF were utilized. Crude (HRc) and adjusted hazard ratios (HRa) were calculated to assess the association between immunization status and COVID-19 mortality. Vaccine effectiveness (VE) was computed as VE% = (1 – HR)*100. A total of 972 adults (52.9% female) with a median age of 42 years were analyzed; 9.4% had comorbidities. Booster immunization demonstrated a significantly lower hazard of death compared to unvaccinated individuals (HRa: 0.06; 95% CI: 0.02–0.23). Booster vaccination is concluded as a critical strategy to reduce COVID-19 mortality and to strengthen public immunization policies. |
|---|